Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ IL1R2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA140298
Description
PA1-40298 detects IL-1R II from human samples. PA1-40298 has been successfully used in ELISA applications. The PA1-40298 imunogen is human IL-1 receptor type II.
The protein encoded by this gene is a cytokine receptor that belongs to the interleukin 1 receptor family. This protein binds interleukin alpha (IL1A), interleukin beta (IL1B), and interleukin 1 receptor, type I(IL1R1/IL1RA), and acts as a decoy receptor that inhibits the activity of its ligands. Interleukin 4 (IL4) is reported to antagonize the activity of interleukin 1 by inducing the expression and release of this cytokine. This gene and three other genes form a cytokine receptor gene cluster on chromosome 2q12. Two alternatively spliced transcript variants encoding the same protein have been reported.
Specifications
IL1R2 | |
Polyclonal | |
Unconjugated | |
Il1r2 | |
antigen CDw121b; CD121 antigen-like family member B; CD121b; CDw121b; IL-1 receptor beta chain; IL-1 type II receptor; Il1r2; Il-1r2; IL-1R-2; Il1r-2; IL1R2c; IL1RB; IL-1R-beta; IL-1RT2; IL-1RT-2; ILR2; interleukin 1 receptor type 2; interleukin 1 receptor type II variant 3; interleukin 1 receptor, type II; interleukin-1 receptor beta; Interleukin-1 receptor type 2; Interleukin-1 receptor type 2, membrane form; Interleukin-1 receptor type 2, soluble form; Interleukin-1 receptor type II; mIL-1R2; sIL-1R2; type II interleukin-1 receptor, beta | |
Rabbit | |
Protein A | |
RUO | |
7850 | |
4°C | |
Liquid |
ELISA | |
0.1 mg/mL | |
PBS with 0.1% BSA and 0.02% sodium azide | |
P27930 | |
Il1r2 | |
Human IL-1 receptor type II. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction